Quick answer: NAD+ (nicotinamide adenine dinucleotide) is a coenzyme present in every living cell, where it shuttles electrons between chemical reactions and serves as a consumable substrate for two enzyme families, the sirtuins and the PARPs. Cells depend on NAD+ to turn food into usable energy and to run DNA repair and signaling work, and measurements in animals and human tissue show NAD+ levels falling with age. Whether raising NAD+ changes how a person feels or functions is a separate question, and the human trials addressing it are still early and small.
Energy, focus and recovery are what most people have in mind when they start reading about NAD+, and the reason the molecule keeps surfacing is that it sits at the center of how cells produce usable energy at all. NAD+ appears in nearly every metabolic pathway a cell runs, which is unusual for a single molecule. Understanding it means separating two distinct jobs: moving electrons, and being spent as a raw material.
What NAD+ actually is
NAD+ is a coenzyme assembled from niacin (a B3 vitamin) and adenine, and cells build it continuously rather than holding a large reserve. Every nucleated cell carries a pool of it, split across the cytosol, the mitochondria and the nucleus, with each compartment regulated somewhat separately. Working equipment describes it better than nutrient does, since the molecule is spent and rebuilt continuously.
Chemically, NAD+ exists in two interconverting forms. Oxidized NAD+ accepts a pair of electrons and becomes NADH; NADH releases those electrons and returns to NAD+. Biochemists describe a cell's state as the ratio between the two, because the ratio determines which reactions can proceed.
Turnover is the part most summaries skip. Certain enzymes cleave NAD+ and consume it outright rather than recycling it, so the pool is rebuilt from precursors continuously. For how that spending interacts with mitochondrial output, read how NAD+ connects to mitochondria and age related energy decline.
How NAD+ carries electrons
Redox chemistry is the first job, and it is why NAD+ runs through glycolysis, fatty acid oxidation and the citric acid cycle. Enzymes in those pathways strip electrons off fuel molecules and hand them to NAD+, producing NADH. Without oxidized NAD+ available to accept electrons, those pathways slow no matter how much fuel is present.
NADH then delivers its electrons to complex I of the electron transport chain in the inner mitochondrial membrane. Moving down that chain, the electrons drive protons across the membrane, and the gradient that builds powers ATP synthase. Regenerating NAD+ at that handoff keeps the upstream pathways turning, which is why the ratio matters more than the absolute amount.
Sirtuins, PARPs and the second job
Sirtuins are enzymes that remove acetyl and related chemical groups from proteins, and they require NAD+ as a substrate to do it. Through those edits, sirtuins influence gene expression, mitochondrial biogenesis and several stress response programs.
PARPs are the other major consumer. Poly(ADP-ribose) polymerases respond to DNA strand breaks by attaching chains of ADP-ribose to proteins at the damage site, and every unit of that chain comes from an NAD+ molecule. Heavy DNA damage therefore draws the pool down quickly, which is why accumulated damage is thought to contribute to lower NAD+ in older tissue.
CD38, an enzyme found on immune and other cells, degrades NAD+ as well, and its activity rises with age in mice. Taken together, these consumers suggest demand climbing rather than production simply failing.
Why NAD+ levels decline with age
Age related decline in NAD+ is well supported. Rodent studies consistently report lower NAD+ in liver, muscle and brain in older animals, and human measurements in skin, skeletal muscle, brain and plasma point the same direction, with the exact rate still being refined.
Mechanistically, three explanations are offered: reduced salvage synthesis, rising consumption by PARPs and CD38, and shifts in how NAD+ is distributed between compartments. Sorting between them in living humans is hard, since sampling tissue is invasive and blood levels do not reflect what is happening inside muscle or brain.
Precursors versus NAD+ itself
Precursors are the compounds cells use to build NAD+, and most products in this category supply a precursor rather than NAD+ itself. Nicotinamide riboside (NR) and nicotinamide mononucleotide (NMN) are the most studied; niacinamide and plain niacin feed the same salvage pathway. Oral NR and NMN both raise blood NAD+ markers in human trials, a real and repeatable result.
Intact NAD+ taken by mouth behaves differently. NAD+ is a large, charged molecule broken down in the gut and intestinal wall before much reaches circulation, so oral NAD+ has poor bioavailability and is largely degraded into precursors along the way. Interest in other routes follows from that, and is covered in how NAD+ IV, subcutaneous and intranasal delivery differ.
Raising a blood marker and producing a clinical effect are two different findings. Several trials confirmed NAD+ metabolites rising after supplementation while measuring no change in the outcomes tracked.
What the human research shows so far
Mechanism and outcome are worth separating cleanly. Everything above is well characterized biochemistry; whether raising NAD+ changes how a person feels or performs is a different question, and the honest position is that most of the encouraging intervention work comes from animal models while human trials remain small and short.
Animal results are genuinely striking, and they are why the field moved quickly: restoring NAD+ in aged mice has improved mitochondrial function, exercise capacity and vascular measures across several well conducted studies. Human trials show precursors raising blood NAD+ markers reliably, with mixed results on functional endpoints, and larger studies are underway. For a method of reading that gap, see how to read preclinical evidence without overreading it.
Frequently Asked Questions
Is NAD+ a vitamin?
NAD+ is not a vitamin; NAD+ is a coenzyme the body builds using B3 vitamins as raw material. Niacin and niacinamide are the dietary forms, and severe deficiency of them causes pellagra, a defined nutritional disease. Ordinary diets supply enough B3 to prevent deficiency, so the NAD+ conversation concerns levels above that threshold.
Does taking NAD+ by mouth work?
Oral intact NAD+ is poorly absorbed, because the molecule is degraded in the digestive tract before it can enter circulation whole. Most of what arrives does so as smaller precursors, so an oral NAD+ product largely functions as a precursor source.
What is the difference between NMN and NR?
NMN and NR are both precursors feeding the salvage pathway, differing by one phosphate group and by the transporters they appear to use. Human trials exist for both, and both raise blood NAD+ markers. Direct head to head human comparisons are limited.
Do NAD+ levels really fall with age?
Age related decline in NAD+ is supported by consistent animal data and by human tissue measurements pointing the same way. Human studies are modest in size and vary in method, so the direction is clearer than the magnitude. Refining that figure is an open research question.
Are sirtuins the reason NAD+ matters?
Sirtuins are one reason NAD+ matters, since they consume it as a substrate while regulating gene expression and mitochondrial programs. Sirtuin biology is well characterized in cell and animal models. Measuring sirtuin activity inside living human tissue is impractical today.
Is NAD+ safe?
Safety findings for NAD+ precursors in short human trials have generally been reassuring, with side effects reported as mild and infrequent. Long term human safety data are limited, mostly because the trials have been short. Any decision about a prescription therapy belongs with a licensed clinician who reviews your history.
The honest summary
NAD+ is well established biochemistry, and the mechanism is not in question: cells cannot run redox metabolism, sirtuin signaling or PARP mediated DNA repair without it. Decline with age is solid in animals and reasonably supported in humans, and precursors measurably raise NAD+ markers in human blood. What the research supports well is the mechanism; what people experience when NAD+ is raised is less settled, and the trials answering that are still early. Holding both together is the accurate position to bring to a clinician.
References
Primary sources for the claims above. Where a study is preclinical, that is stated in the section it supports.
NAD(+) metabolism and its roles in cellular processes during ageing. Nature reviews. Molecular cell biology. 2021. PMID 33353981.
NAD+ and sirtuins in aging and disease. Trends in cell biology. 2014. PMID 24786309.
Compounded medications are not FDA-approved and are not the same as, nor a substitute for, FDA-approved products. Prescription products require an evaluation by a licensed provider who determines whether a prescription is appropriate. A prescription is not guaranteed. Individual results vary. Everhuman does not provide medical advice; clinical care is delivered by Arora Health.